Steve Clark

Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.
EV Energy Partners, L.P. (NASDAQ:EVEP)

EV Energy Partners, L.P. (NASDAQ:EVEP) Stock Booms!

EV Energy Partners, L.P. (NASDAQ:EVEP)

EV Energy Partners, L.P. (NASDAQ:EVEP) shares broke above six-month resistance levels and more than doubled since early September. EVEP stock ended Thursday’s trading session at $0.77 then opened today at $0.78 before rocketing to an inter-day high of $1.16 on heavy volume. EVEP shares have an average trading volume under 200,000 shares but today almost 3 million shares have exchanged hands with 30 minutes left in the trading day.

NASDAQ:EVEP

EV Energy Partners, L.P. (NASDAQ:EVEP), based in Houston, TX, specializes in the acquisition, operation, and development of onshore oil and gas properties in the USA. Operations are currently ongoing at the Barnett Shale, the San Juan Basin, the Appalachian Basin, Michigan, Central Texas, the Monroe Field in Northern Louisiana, the Mid–Continent areas in Oklahoma, Texas, Arkansas, Kansas and Louisiana and the Permian Basin.

EVEP Stock Performance

Between the second week in June and the end of October, EV Energy Partners, L.P. (NASDAQ:EVEP) stock had a trading range between $0.40 and $0.80. The shares had established a new 52-week low in mid-August of $0.37. However in the last seven trading sessions, EVEP stock has gone from $0.60 to today’s high of $1.16.

In 2016, EVEP stock received five ratings downgrades from analysts. Five investment firms follow EV Energy Partners, L.P. (NASDAQ:EVEP). Four rate EVEP shares as a “Hold” and one rates the shares as a “Underperform”. YTD, EVEP has underperformed the sector by around 40%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EVEP and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Aratana Therapeutics Inc (NASDAQ:PETX) Jumps

Aratana Therapeutics Inc (NASDAQ:PETX)

The market reacted favorably to the earnings release by Aratana Therapeutics Inc (NASDAQ:PETX) and it shares have risen over 18% on heavy volume. After the market closed yesterday, the pet therapeutics company reported total net revenues of $6.2 million and a net loss of (-$8.9) million or (-$0.21) diluted loss per share. According to Zacks Investment Research, analysts were expecting a per share loss of (-$0.26).

Aratana Therapeutics Inc (NASDAQ:PETX)

Founded in 2010, Aratana Therapeutics Inc (NASDAQ:PETX) has its headquarters in Leawood, Kansas. Aratana is a pet therapeutics company that licenses, develops and commercializes therapeutics for dogs and cats in the United States and Belgium. Its product portfolio includes multiple therapeutics, and therapeutic candidates in development, consisting of small molecule pharmaceuticals and biologics.

Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to dogs and cats in a capital and time efficient manner. Aratana’s pipeline includes therapeutic candidates for the potential treatment of pain, inappetence, viral diseases, allergy, cancer and other serious medical conditions.

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics Inc (NASDAQ:PETX) commented on the earnings results, “With the launch of NOCITA, GALLIPRANT and now ENTYCE, Aratana is well-positioned to extend the relationships we have been building within specialty and general practice veterinary clinics over the past year. Aratana continues to remain focused on developing and commercializing innovative pet therapeutics, which we believe is the most underserved and attractive segment of the animal health market.”

PETX Q3 Earnings

The company’s Q3 net loss was (-$8.9) million or (-$0.21) diluted loss per share compared to net loss of (-$13.4) million or (-$0.38) diluted loss per share for the same quarter last year. Aratana recorded $6.2 million in net revenues for Q3, which primarily includes approximately $4.0 million of product sales and $2.2 million in GALLIPRANT licensing and collaboration revenue.

Q3 research and development expenses totaled $3.2 million in comparison to $5.3 million for Q3 2016. Selling, general and administrative expenses totaled $6.9 million in the third quarter ended September 30, 2017 and $21.3 million for the nine-month period ended September 30, 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PETX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Insignia Systems, Inc. (NASDAQ:ISIG) Explodes on Earnings Surprise

Insignia Systems, Inc. (NASDAQ:ISIG)

Insignia Systems, Inc. (NASDAQ:ISIG) stock was up over 80% in morning trading after the company released their Q3 earnings yesterday after the market closed. The global consumer marketing firm reported increases in Net Sales, Gross Profit, and Net Income.

ISIG stock closed yesterday at $1.36, then gapped up to open at $1.58 before hitting the inter-day high of $2.19. While ISIG shares are down year-to-date, and for the past year, they are up over 35% during the past quarter.

Insignia Systems, Inc. (NASDAQ:ISIG)

Q3 Earnings

Net sales increased 19.4% to $7,723,000 in Q3 2017, from $6,469,000 in Q3 2016, primarily due to a 30.4% increase in the number of signs placed. Gross profit in Q3 2017 increased to $2,743,000, or 35.5% of net sales, from $2,000,000, or 30.9% of net sales, in Q3 2016. The increased gross profit was primarily due to an increase in sales and a decrease in cost of services due to the discontinued sale of The Like Machine. Gross profit is highly dependent on sales levels due to the relatively fixed nature of a portion of Insignia’s payments to retailers. Net income for Q3 2017 was $451,000, or $0.04 per basic and diluted share, compared to a net loss of -$167,000, or (-$0.01) per basic and diluted share, for the same period last year.

Insignia Systems, Inc. (NASDAQ:ISIG) President and CEO Kristine Glancy commented, “We are pleased with our quarterly results, having delivered both top and bottom line growth. The quarterly results reflect the continued progress against our strategic initiatives with the addition of new CPG customers, strengthening the relationships with existing clients, and gaining traction on business development projects. These strategic initiatives are expected to positively impact the remainder of 2017 and beyond.”

ISIG Stock

The consensus, one-year price target for ISIG stock is $3.00. Insignia Systems, Inc. (NASDAQ:ISIG) reported a per share loss for 2016 of (-$0.11) on sales of $24.9 million. However, it appears that management has set the course for a more profitable 2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ISIG and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Second Sight Medical Products Inc (NASDAQ:EYES),

Good News for Second Sight Medical Products Inc (NASDAQ:EYES)

Second Sight Medical Products Inc (NASDAQ:EYES)

Shares of Second Sight Medical Products Inc (NASDAQ:EYES), headquartered in Sylmar, CA, are up over 10% in late trading on the back of a ten-fold volume increase. The strong move upwards was a result of investor reaction to the consent of the U.S. Food and Drug Administration (FDA) to begin the Orion™ Cortical Visual Prosthesis System (Orion) feasibility clinical study. The approval allows two U.S. sites, the University of California at Los Angeles (UCLA) and Baylor College of Medicine (Baylor) in Houston, to enroll up to five total patients.

Second Sight Medical Products Inc (NASDAQ:EYES),

Second Sight Medical Products Inc (NASDAQ:EYES)’s develops, manufactures, and markets innovative implantable visual prosthetics to enable blind individuals to achieve greater independence. Second Sight’s Orion™ Visual Cortical Prosthesis is being developed to restore some vision to individuals who are blind due to causes other than preventable or treatable conditions.

Will McGuire, President and CEO of Second Sight stated ““We remain on track toward achieving our stated goal of implanting our first Orion patient before year end, and the potential opportunity to provide useful vision to millions of blind individuals worldwide who have no other option today,”

EYES Stock Performance

Despite the science fiction nature of their product that could change the lives of millions of blind people, current financial results have been poor for shareholders. In late 2015, EYES stock was trading above $7, but a lack of profits has seen a downward trend for the shares. In February of 2017, EYES stock briefly rose near $3, but during most of the past year has had the stock below the $2 level.

EYES stock is down 55% for the year, and down 4% for the past month. There is a moderate short position on the company – over 10% of the share’s float is held as a short position.

HC Wainwright covers Second Sight Medical Products Inc (NASDAQ:EYES) and assigns EYES stock a “Strong Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $EYES and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) Continues Move Higher

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) shares are up 31%, to $7.36, on news of a research collaboration and license agreement with Boehringer Ingelheim to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases. Under the terms of the agreement, Dicerna may receive more than $200 million in upfront, development and commercial milestone payments, and research and development reimbursement for a GalXC candidate product addressing an undisclosed NASH target. Dicerna is also eligible to receive royalties staggered up to double-digits on worldwide net sales.

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA)

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA), based in Cambridge, MA, discovers and develops RNAi-based therapeutics for diseases involving the liver, including rare diseases, chronic liver diseases, cardiovascular diseases, and viral infectious diseases. Dicerna is leveraging its proprietary GalXC™ RNAi technology platform to build a broad pipeline in these core therapeutic areas, focusing on target genes where there are recognized connections between the target gene and diseases.

Dicerna’s GalXC technology platform uses RNAi to inhibit the expression of disease-causing genes by destroying the messenger RNAs (mRNAs) of those genes. This new approach has the potential to treat diseases by silencing previously inaccessible drug targets.

Douglas M. Fambrough, President and Chief Executive Officer of Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) stated, “With strong capabilities in drug discovery, deep expertise in the cardiometabolic space, and proven commercial experience, Boehringer Ingelheim is a natural partner to speed the development of the first GalXC RNAi program targeting chronic liver disease. The collaboration combines the strong capabilities of both companies to pursue the full potential of Dicerna’s GalXC technology to bring valuable and differentiated RNAi therapies to patients with liver diseases and their healthcare teams, and reflects both the promise of the GalXC technology and the strength of its underlying intellectual property.”

DRNA Stock Performance

Five investment firms follow Dicerna Pharmaceuticals Inc (NASDAQ:DRNA). Four rate DRNA shares as a “Strong Buy” and one rates the shares as a “Hold”.

In 2016, DRNA shareholders saw a per share loss of (-$2.87) on total sales of just $300,000. Despite those numbers, shareholders have seen a year-to-date gain of over 95%. Today’s price action (currently at $7.36) eclipses the previous 52-week high of $6.75 and also tops analyst’s consensus one-year price target of $5.75.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $DRNA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

NII Holdings, Inc. (NASDAQ:NIHD) And Lenders Reach Agreement

NII Holdings, Inc. (NASDAQ:NIHD)

Shares of NII Holdings, Inc. (NASDAQ:NIHD) gained 4.55% after the mobile communication services provider announced the restructuring of a loan agreement with China Development Bank, Banco do Brazil, and Caixa Economica Federal. The changes include the deferral of principal payments for the first 48 months from the date of effectiveness.

NII Holdings, Inc. (NASDAQ:NIHD)

Loan Amendments

Wednesday’s rally helped push the stock slightly above its 52-week low of $0.36 a share. However, the stock continues to trade in a strong downtrend after underperforming the overall industry for the better part of the year. The stock is down by more than 80% for the year.

Amidst the underperformance, Chief Financial Officer, Dan Freiman remains upbeat about NII Holdings, Inc. (NASDAQ:NIHD) prospects,

“The signing of the amendments marks a significant milestone in our efforts to improve our financial outlook and liquidity and will enable us to continue to invest in and grow our business in Brazil. We are actively working to obtain the final approvals necessary for the amendments to become effective,” said Mr. Freiman.

The proposed amendments include a compliance holiday for certain financial covenants including the net debt financial covenant until June 30, 2020. The amendments also include a loan maturity date of 98 months. NII Holdings, Inc. (NASDAQ:NIHD), through Nextel Brazil, is to grant an additional security interest to each of its lenders in the form of preferential rights as part of the agreement. The amendments are still subject to approval by Sinosure on or before December 31, 2017.

 

Q2 Financial Results

NII Holdings, Inc. (NASDAQ:NIHD) reported a net loss of (-$84.8) million or (-$0.85) cents a share for the second quarter. Revenue in the quarter totaled $225 million. Capital expenditure in the quarter totaled $9 million. The company exited the quarter with a 29,000 3G net subscriber losses and 104,000 subscriber losses.

According to Chief Executive Officer, Roberto Rittes, the quarter highlighted improved operating cash flow efficiency due to increased focus on improving liquidity.

“In addition, during the quarter, other operators introduced more aggressive rate plans that affected our subscriber growth and churn. In response to this development, in August, we introduced new rate plans that we believe will compete well against the new offers in the market,” said Mr. Rittes.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NIHD and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Vermillion, Inc. (NASDAQ:VRML) Stock Jumps!

Vermillion, Inc. (NASDAQ:VRML)

Vermillion, Inc. (NASDAQ:VRML) stock is up over 33% in early afternoon trading after the company’s subsidiary announced that it expanded positive policy coverage with the addition of 14 key managed care providers. VRML stock opened at $1.51, also today’s low, and shot up to hit an inter-day high of $1.97. VRML shares are trading around $1.88 at the time of this writing (12:38 PM EST).

Vermillion, Inc. (NASDAQ:VRML)

Austin, TX-based Vermillion, Inc. (NASDAQ:VRML) discovers, develops, and commercializes diagnostic and bio-analytical solutions that aid physicians to diagnose, treat, and improve gynecologic health. Vermillion, along with its scientific collaborators, discovers, develops, and delivers innovative diagnostic and technology tools that help women with serious diseases. One of the company’s subsidiaries is ASPiRA Labs – the exclusive distributor of OVA1 (Multivariate Index Assay) (MIA).

Vermillion Subsidiary Coverage Details

ASPiRA Labs established positive coverage policies specify that OVA1 is medically necessary for the below plans:

  • BlueCross BlueShield (BCBS) plans associated with a national plan, Health Care Service Corporation (HCSC) that include Illinois, Montana, New Mexico, Oklahoma and Texas (approximately 14.8 million covered lives)
  • Horizon BCBS plans in New Jersey (approximately 3.7 million covered lives)
  • Highmark BCBS plans that include Pennsylvania, West Virginia and Delaware (approximately 3.2 million covered lives)
  • Wellcare: Government sponsored managed care across the U.S. (approximately 2.9 million covered lives)

Fred Ferrara, Chief Operating Officer of Vermillion, Inc. (NASDAQ:VRML) stated “Two policies totaling approximately 3.8 million covered lives are effective as of October 1, 2017, with the remainder being effective January 2018. This positive policy coverage is the first step to in-network contracts and market adoption. We are finishing this year strong with managed care rapidly increasing support of OVA1 to over 123 million lives, as of January 2018.  OVA1 provides the only pelvic mass risk assessment product proven to get patients to the highest standard of care for ovarian cancer treatment.”

VRML Stock Performance

VRML stock is currently trading above the analysts’ consensus price target of $1.75. Its 52-week low is $0.76 and its 52-week high is $2.85.

Earnings losses have been contracting over the past three years. In 2014 the per share loss was (-$0.53), followed in 2015 by a loss of (-$0.41), and a narrower loss for 2016 of (-$0.29).

Dilution remains a concern though. In 2012 there were 15.1 million shares outstanding. That number has increased every year and for 2016 the company reported 52.2 million shares were outstaning.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $VRML and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)

Legal Issues Settled for Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)?

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)

Bethesda, MD-based Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) shares are off 5% after the company announced “meaningful progress” in resolving four lawsuits that were brought against it. The company announced that it expects to not pay any monetary damages.

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)

The Lawsuits

The lawsuit filed in a Maryland court included a variety of claims about alleged false reporting concerning results of the DCVax-Direct Phase I trial and the DCVax-L Phase III GBM trial, among other things.

Another lawsuit filed in Delaware and Maryland was a class action lawsuit on behalf of the Company and its shareholders naming Cognate, various Toucan entities, and NW Bio’s Board of Directors as defendants and seeking disgorgement of purportedly improper benefits and an unspecified amount of damages, among other relief.

The last lawsuit was filed in Maryland and was an amalgam of accusations detailed above.

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO) CEO Linda Powers stated “lawsuits like these can be a distraction from the important work of companies like ours. In my opinion, disposing of these cases is an important step forward in our vindication from the relentless and false campaign to discredit our science, our operations and our ethics, and hopefully helps remove what have been delaying obstacles in our path forward.  These resolutions come with no further price tag to shareholders, allowing us to focus our resources on the Company’s mission of providing our promising vaccines to as many solid tumor cancer patients as possible, at the earliest time possible.”

About Northwest Biotherapeutics, Inc.

Northwest Biotherapeutics, Inc (OTCMKTS:NWBO)is a biotechnology company that develops personalized immunotherapy products designed to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The company has operations and sales in both the North America and Europe.

NWBO Stock Performance

The consensus one-year price target for NWBO stock is $5.00. However, today the shares hit a new low of $0.16. 10% of the shares float is held by short-sellers.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $NWBO and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Payment Data Systems, Inc. (NASDAQ:PYDS)

Payment Data Systems, Inc. (NASDAQ:PYDS) Post Record Processing Activity

Payment Data Systems, Inc. (NASDAQ:PYDS)

San Antonio, TX-based Payment Data Systems, Inc. (NASDAQ:PYDS) stock rose over 80% after the payment processor announced that its transactions processing volumes for the third quarter of 2017 set an all-time record. PYDS stock closed at $2.59 on a volume figure that was over 150 times the listed daily average. Total dollars processed for the third quarter of 2017 exceeded $704.9 million.

Payment Data Systems, Inc. (NASDAQ:PYDS)

Louis Hoch, President and CEO of Payment Data Systems, stated, “The successful execution of our revenue growth plan is now yielding results. We are pleased at the dramatic growth in the credit card processing segment of our business, and are also pleased to see the growth in our ACH business as compared to second quarter’s downturn. We now have visibility into continued revenue growth throughout the rest of 2017 and for all of 2018.”

Payment Data Systems, Inc. (NASDAQ:PYDS) is an integrated payment solutions provider, and offers a wide range of payment solutions to merchants, billers, banks, service bureaus, and card issuers. The Company operates credit, debit/prepaid and ACH payment processing platforms to deliver convenient, world-class payment solutions and service to their clients.

One year ago, Payment Data Systems, Inc. (NASDAQ:PYDS) hot their 52-week high of $2.65 – $0.06 above today’s losing price. After that high was hit, PYDS shares slid over the next 6-8 months and established a new 52-week low of $1.17. Over the past year the shares have done well – up over 25%. Year-to-date they have performed even better – up 40%.

Analysts have given PYDS stock a consensus one-year price target of $8 even as the shares have been projected to post negative earnings of 20%.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PYDS and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

LightPath Technologies, Inc. (NASDAQ:LPTH)

LightPath Technologies, Inc. (NASDAQ:LPTH) Continues to Jet Higher

LightPath Technologies, Inc. (NASDAQ:LPTH)

LightPath Technologies, Inc. (NASDAQ:LPTH) has recorded a new inter-day 52-week high, $4.10, on volume that is five times the listed daily average. While the broad market indexes are all pulling back, LPTH shares are on track to post a 27% gain in just the past week.

LightPath Technologies, Inc. (NASDAQ:LPTH)

Orlando, FL-based LightPath Technologies, Inc. (NASDAQ:LPTH) is a vertically integrated provider of optics, photonics and infrared solutions for the global industrial, defense, telecommunications, testing and measurement, and medical industries. LightPath designs, manufactures, and distributes proprietary optical and infrared components including molded glass aspheric lenses and assemblies, infrared lenses and thermal imaging assemblies, fused fiber collimators, and gradient index GRADIUM® lenses. LightPath also offers custom optical assemblies, including full engineering design support.

LPTH Stock Performance

Shareholders of LightPath Technologies, Inc. (NASDAQ:LPTH) have fared well in 2017. Year-to-date, LPTH shares are up over 143%. This high level of performance is also reflected in the stock’s Relative Strength Index (RSI) figure of 86. Many investors and traders believe a figure over 70 reflects an “overbought” condition in a security, however LPTH shares have been over 70 for at least a month and the market seems to believe that higher prices are justified by recent earnings which are up 300% over the previous year. Financial analysts are expecting earnings growth for next year to be around 22%.

In 2015, LightPath posted a per share loss of ($0.05) but followed that in 2016 with a profit of ($0.09) per share, and profit of ($0.39) in FY2017. Sales have followed a similar path. For 2014, LightPath Technologies, Inc. (NASDAQ:LPTH) reported sales of $11.8 million. That number increased every year and in FY2017 the number was $28.4 million.

Two investment firms follow LightPath Technologies, Inc. (NASDAQ:LPTH). Both rate the shares as a “Buy”.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $LPTH and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.